[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100399869":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":43,"centralContacts":47,"locations":57,"responsibleParty":239,"collaborators":52,"id":241,"slug":242,"hasResults":243,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":243,"sex":249,"minAge":250,"maxAge":52,"enrollmentInfo":251,"targetDuration":52,"studyType":254,"phases":255,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":60,"whyStopped":52,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":277},{"fullName":5,"class":6},"Genprex, Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Investigational","EXPERIMENTAL","In Phase 1, Phase 2a and the investigational arm of Phase 2b, patients will receive their assigned dose of quaratusugene ozeplasmid (intravenous administration once every 21 days) plus osimertinib (80 mg fixed dose oral tablet taken daily starting on Day 1 through Day 21 of every 21-day treatment cycle) until disease progression or unacceptable toxicity.",[13,14],"Biological: quaratusugene ozeplasmid","Drug: osimertinib",{"label":16,"type":17,"description":18,"interventionNames":19},"Control","ACTIVE_COMPARATOR","In the control arm of Phase 2b, patients will receive platinum-based chemotherapy until disease progression or unacceptable toxicity.",[20],"Drug: Platinum-Based Chemotherapy",[22,29,36],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"BIOLOGICAL","quaratusugene ozeplasmid","Quaratusugene ozeplasmid is an experimental non-viral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.",[9],[28],"Reqorsa",{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","osimertinib","Osimertinib is a 3rd generation EGFR tyrosine kinase inhibitor (TKI) oral tablet administered daily, as indicated for treatment of patients with metastatic NSCLC whose tumors have EGFR genetic deletions or mutations.",[9],[35],"Tagrisso",{"type":30,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Platinum-Based Chemotherapy","Cisplatin and carboplatin are intravenously administered platinum agents that are combined with other cytotoxic chemotherapy agents such as pemetrexed.",[16],[41,42],"cisplatin","carboplatin",[44],{"name":45,"affiliation":5,"role":46},"Mark S. Berger, MD","STUDY_DIRECTOR",[48,54],{"name":49,"role":50,"phone":51,"phoneExt":52,"email":53},"Sr Director, Clinical Operations","CONTACT","1-877-774-GNPX",null,"kcombs@genprex.com",{"name":55,"role":50,"phone":51,"phoneExt":52,"email":56},"Chief Medical Officer","mberger@genprex.com",[58,80,102,119,136,156,173,195,206,223],{"facility":59,"status":60,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"Valkyrie Clinical Trials","RECRUITING","Los Angeles","California","90067","United States","US",{"type":67,"coordinates":68},"Point",[69,70],-118.24368,34.05223,{"lat":70,"lon":69},[73,77],{"name":74,"role":50,"phone":75,"phoneExt":52,"email":76},"Kristi Okino","562-833-1483","Kristi.okino@valkyrieclinicaltrials.com",{"name":78,"role":79,"phone":52,"phoneExt":52,"email":52},"David Berz, MD","PRINCIPAL_INVESTIGATOR",{"facility":81,"status":60,"city":82,"state":83,"zip":84,"country":64,"countryCode":65,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Rocky Mountain Cancer Centers","Lone Tree","Colorado","80124",{"type":67,"coordinates":86},[87,88],-104.8863,39.55171,{"lat":88,"lon":87},[91,96,100],{"name":92,"role":50,"phone":93,"phoneExt":94,"email":95},"Katherine Schleich","303-285-5018","35018","Katherine.schleich@usoncology.com",{"name":97,"role":50,"phone":98,"phoneExt":52,"email":99},"Joni Richman","303-336-2181","joni.richman@usoncology.com",{"name":101,"role":79,"phone":52,"phoneExt":52,"email":52},"Robert M. Jotte, MD",{"facility":103,"status":60,"city":104,"state":105,"zip":106,"country":64,"countryCode":65,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"Carle Cancer Institute","Urbana","Illinois","61801",{"type":67,"coordinates":108},[109,110],-88.20727,40.11059,{"lat":110,"lon":109},[113,117],{"name":114,"role":50,"phone":115,"phoneExt":52,"email":116},"Hannah Parks","217-326-3150","Hannah.Parks@carle.com",{"name":118,"role":79,"phone":52,"phoneExt":52,"email":52},"Kendrith Rowland, MD",{"facility":120,"status":60,"city":121,"state":122,"zip":123,"country":64,"countryCode":65,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Markey Cancer Center","Lexington","Kentucky","40536",{"type":67,"coordinates":125},[126,127],-84.47772,37.98869,{"lat":127,"lon":126},[130,134],{"name":131,"role":50,"phone":132,"phoneExt":52,"email":133},"Morgan Butler","859-562-0318","Morgan.Butler@uky.edu",{"name":135,"role":79,"phone":52,"phoneExt":52,"email":52},"Zhonglin Hao, MD",{"facility":137,"status":60,"city":138,"state":139,"zip":140,"country":64,"countryCode":65,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"Maryland Oncology Hematology","Rockville","Maryland","20850",{"type":67,"coordinates":142},[143,144],-77.15276,39.084,{"lat":144,"lon":143},[147,151,154],{"name":148,"role":50,"phone":149,"phoneExt":52,"email":150},"Missy Almand","877-664-7724","missy.almand@usoncology.com",{"name":152,"role":50,"phone":149,"phoneExt":52,"email":153},"Jake Brooks","jake.brooks@usoncology.com",{"name":155,"role":79,"phone":52,"phoneExt":52,"email":52},"John M. Wallmark, MD",{"facility":157,"status":60,"city":158,"state":159,"zip":160,"country":64,"countryCode":65,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"The Valley Hospital - Luckow Pavilion","Paramus","New Jersey","07652",{"type":67,"coordinates":162},[163,164],-74.07542,40.94454,{"lat":164,"lon":163},[167,171],{"name":168,"role":50,"phone":169,"phoneExt":52,"email":170},"Robyn Chicherchia","201-634-5792","rchiche@valleyhealth.com",{"name":172,"role":79,"phone":52,"phoneExt":52,"email":52},"Eli D. Kirshner, MD",{"facility":174,"status":60,"city":175,"state":176,"zip":177,"country":64,"countryCode":65,"cosmosGeoPoint":178,"geoPoint":182,"contacts":183},"Gabrail Cancer Center Research","Canton","Ohio","44718",{"type":67,"coordinates":179},[180,181],-81.37845,40.79895,{"lat":181,"lon":180},[184,188,193],{"name":185,"role":50,"phone":186,"phoneExt":52,"email":187},"Carrie Smith","330-417-8231","csmith@gabrailcancercenter.com",{"name":189,"role":50,"phone":190,"phoneExt":191,"email":192},"Kim Roby","330.492.3345","227","kroby@gabrailcancercenter.com",{"name":194,"role":79,"phone":52,"phoneExt":52,"email":52},"Nashat Gabrail, MD",{"facility":196,"status":197,"city":198,"state":199,"zip":200,"country":64,"countryCode":65,"cosmosGeoPoint":201,"geoPoint":205,"contacts":52},"Millennium Oncology","TERMINATED","Houston","Texas","77090",{"type":67,"coordinates":202},[203,204],-95.36327,29.76328,{"lat":204,"lon":203},{"facility":207,"status":60,"city":208,"state":209,"zip":210,"country":64,"countryCode":65,"cosmosGeoPoint":211,"geoPoint":215,"contacts":216},"Virginia Cancer Specialists","Fairfax","Virginia","22031",{"type":67,"coordinates":212},[213,214],-77.30637,38.84622,{"lat":214,"lon":213},[217,221],{"name":218,"role":50,"phone":219,"phoneExt":52,"email":220},"Carrie Friedman, RN, BSN, OCN","703-636-1473","carrie.friedman@usoncology.com",{"name":222,"role":79,"phone":52,"phoneExt":52,"email":52},"Alexander I. Spira, MD",{"facility":224,"status":60,"city":225,"state":209,"zip":226,"country":64,"countryCode":65,"cosmosGeoPoint":227,"geoPoint":231,"contacts":232},"Virginia Oncology Associates","Norfolk","23502",{"type":67,"coordinates":228},[229,230],-76.28522,36.84681,{"lat":230,"lon":229},[233,237],{"name":234,"role":50,"phone":235,"phoneExt":52,"email":236},"Tamaura Wilson, RN, BSN, OCN","757-213-5906","Tamaura.wilson@usoncology.com",{"name":238,"role":79,"phone":52,"phoneExt":52,"email":52},"Boon Kok, MD",{"type":240,"investigatorFullName":52,"investigatorTitle":52,"investigatorAffiliation":52,"oldNameTitle":52,"oldOrganization":52},"SPONSOR","100399869","phase-1-quaratusugene-ozeplasmid-reqorsa-and-osimertinib-in-patients-with-advanced-lung-cancer-who-progressed-on-osimertinib-100399869",false,"NCT04486833","Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib","A Phase 1\u002F2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer","Acclaim-1","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Histologically or cytologically documented NSCLC.\n3. Stage III or IV NSCLC or recurrent NSCLC that is not potentially curable by radiotherapy or surgery.\n4. The NSCLC must be epidermal growth factor receptor (EGFR) mutation positive-positive based on results from most recent tissue biopsy or most recent evaluation of circulating tumor DNA.\n5. Achieved clinical response to osimertinib for ≥4 months, which can be a response of stable disease. Must have a minimum of a 10-day osimertinib washout completed at the time of enrollment.\n6. Must have radiological progression on osimertinib treatment and can have either asymptomatic disease or symptomatic disease. In addition:\n\n   1. Must have measurable disease per RECIST 1.1.\n   2. Must have progression on osimertinib treatment as a single agent or in combination with other anti-cancer agents as their most recent treatment.\n\n   Notes:\n   * Patients may have had treatment with other EGFR inhibitors as single agents prior to osimertinib.\n   * Patients may have progression on osimertinib treatment being used for adjuvant therapy after surgery.\n7. Eastern Cooperative Oncology Group performance status (ECOG PS) score from 0 to 1.\n8. Must be ≥28 days beyond major surgical procedures such as thoracotomy, laparotomy, or joint replacement and must not have evidence of wound dehiscence, active wound infection, or comparable major residual complications of the surgery per Investigator assessment.\n9. Asymptomatic brain metastases must meet ALL criteria of the following (a-d):\n\n   1. No history of seizures in the preceding six months.\n   2. Definitive treatment must be completed ≥21 days.\n   3. Must be off steroids administered because of brain metastases or related symptoms for ≥7 days.\n   4. Post-treatment imaging must demonstrate stability or regression of the brain metastases.\n10. Must have and be willing to submit a prior tumor biopsy or undergo a biopsy during Screening to obtain tumor tissue for submission to a central laboratory for IHC analysis and FISH or qPCR testing.\n11. Absolute neutrophil count (ANC) \\>1500\u002Fmm3, platelet count \\>100,000\u002Fmm3 within ≤28 days.\n12. Adequate renal function documented by serum creatinine of ≤1.5 mg\u002FdL or calculated creatinine clearance \\>50 ml\u002Fmin within ≤28 days.\n13. Adequate hepatic function as documented by serum bilirubin \\\u003C1.5 mg\u002FdL and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 X upper limit of normal (ULN) within ≤28 days.\n14. Stable cardiac condition with a left ventricular ejection fraction ≥40% within ≤28 days.\n15. If female of childbearing potential (FOCBP), must have negative serum pregnancy test (serum beta-human chorionic gonadotropin \\[β-hCG\\]) within ≤7 days.\n16. FOCBP and non-sterile male patients with female partner(s) of childbearing potential must agree to use two forms of contraception including one highly effective and one effective method beginning ≥2 weeks prior to enrollment through four months following the last dose of study treatment.\n17. If male, must agree to no sperm donation during study treatment and for an additional four months following the last dose of study treatment.\n18. Must have voluntarily signed an informed consent in accordance with institutional policies.\n\nExclusion Criteria:\n\n1. Unable to tolerate osimertinib treatment, leading to early treatment discontinuation or prolonged\u002Ffrequent dosage modifications as determined by the Investigator.\n2. Received prior gene therapy.\n3. Other genetic characteristics (such as ALK, ROS, BRAF V600E mutations) which make them a candidate for treatment with other approved targeted therapies.\n4. Received radiotherapy to the skull, spine, thorax, or pelvis within ≤30 days.\n5. Active concurrent malignancies, i.e., cancers other than NSCLC that require systemic therapy.\n6. Active systemic viral, bacterial, or fungal infection(s) requiring treatment.\n7. Serious concurrent illness or psychological, familial, sociological, geographical, or other concomitant conditions that, in the opinion of the Investigator, would not permit adequate follow-up and compliance with the study protocol.\n8. History of myocardial infarction or unstable angina within ≤6 months.\n9. Known human immunodeficiency virus (HIV) infection or has active hepatitis infection.\n10. Female who is pregnant or breastfeeding.","ALL","18 Years",{"count":252,"type":253},158,"ESTIMATED","INTERVENTIONAL",[256,257],"PHASE1","PHASE2","The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. Quaratusugene ozeplasmid consists of non-viral lipid nanoparticles that encapsulate a DNA plasmid with the TUSC2 tumor suppressor gene and is the first systemic gene therapy for cancer.\n\nThe study is comprised of a Phase 1 dose escalation portion and two Phase 2 portions evaluating safety and efficacy. Enrollment in the Phase 1 dose escalation portion is complete and the recommended Phase 2 dose (RP2D) was determined. Phase 2a has initiated and enrolled patients are treated with quaratusugene ozeplasmid at the RP2D in combination with osimertinib. In Phase 2b, patients will be randomized to receive either quaratusugene ozeplasmid plus osimertinib or platinum-based chemotherapy.",[260],"Carcinoma, Non-Small Cell Lung",[262,31,263,264,265,35,266,267,28,24],"Epidermal growth factor receptor mutation (EGFR)","Tumor suppressor gene 2 (TUSC2)","Lipid nanoparticle (LNP)","Gene therapy","FUS1-nanoparticles","NSCLC","2026-01-20",{"date":270,"type":271},"2026-01-21","ACTUAL",{"date":273,"type":271},"2021-09-03",{"date":275,"type":253},"2029-03",{"name":5,"class":6},10]